Latest period
$2.62B
YoY change
-8.2%
5Y CAGR
-4.1%
Peak year (2021)
$32.58B
Latest annual
$11.71B
Operating Cash Flow history chart for Pfizer (PFE) from 1989 to 2025
Latest: $11.71B
Operating Cash Flow growth chart for Pfizer (PFE) from 1989 to 2025
Latest: -8.2%
Operating Cash Flow history table for Pfizer (PFE) from 1989 to 2025
| 2025 | $11.71B | -8.2% | −$1.04B | ||
| 2024 | $12.74B | +46.5% | +$4.04B | ||
| 2023 | $8.70B | -70.3% | −$20.57B | ||
| 2022 | $29.27B | -10.2% | −$3.31B | ||
| 2021 | $32.58B | +126.2% | +$18.18B | ||
| 2020 | $14.40B | +14.4% | +$1.81B | ||
| 2019 | $12.59B | -20.5% | −$3.24B | ||
| 2018 | $15.83B | -3.9% | −$643.00M | ||
| 2017 | $16.47B | +3.6% | +$569.00M | ||
| 2016 | $15.90B | +9.6% | +$1.39B | ||
| 2015 | $14.51B | -14.0% | −$2.37B | ||
| 2014 | $16.88B | -5.0% | −$882.00M | ||
| 2013 | $17.77B | +4.2% | +$711.00M | ||
| 2012 | $17.05B | -15.7% | −$3.19B | ||
| 2011 | $20.24B | +76.7% | +$8.79B | ||
| 2010 | $11.45B | -30.9% | −$5.13B | ||
| 2009 | $16.59B | -9.1% | −$1.65B | ||
| 2008 | $18.24B | +36.6% | +$4.88B | ||
| 2007 | $13.35B | -24.1% | −$4.24B | ||
| 2006 | $17.59B | +19.4% | +$2.86B | ||
| 2005 | $14.73B | -9.8% | −$1.61B | ||
| 2004 | $16.34B | +39.2% | +$4.60B | ||
| 2003 | $11.74B | +15.3% | +$1.56B | ||
| 2002 | $10.18B | +9.9% | +$920.00M | ||
| 2001 | $9.26B | +49.5% | +$3.07B | ||
| 2000 | $6.20B | +102.7% | +$3.14B | ||
| 1999 | $3.06B | +4.3% | +$127.00M | ||
| 1998 | $2.93B | +79.8% | +$1.30B | ||
| 1997 | $1.63B | -21.2% | −$438.00M | ||
| 1996 | $2.07B | +13.5% | +$245.60M | ||
| 1995 | $1.82B | +22.4% | +$332.90M | ||
| 1994 | $1.49B | +17.9% | +$225.50M | ||
| 1993 | $1.26B | +56.5% | +$456.00M | ||
| 1992 | $807.00M | -4.8% | −$40.60M | ||
| 1991 | $847.60M | -1.5% | −$12.90M | ||
| 1990 | $860.50M | +31.2% | +$204.70M | ||
| 1989 | $655.80M | — | — |
- 2025$11.71B-8.2%
- 2024$12.74B+46.5%
- 2023$8.70B-70.3%
- 2022$29.27B-10.2%
- 2021$32.58B+126.2%
- 2020$14.40B+14.4%
- 2019$12.59B-20.5%
- 2018$15.83B-3.9%
- 2017$16.47B+3.6%
- 2016$15.90B+9.6%
- 2015$14.51B-14.0%
- 2014$16.88B-5.0%
- 2013$17.77B+4.2%
- 2012$17.05B-15.7%
- 2011$20.24B+76.7%
- 2010$11.45B-30.9%
- 2009$16.59B-9.1%
- 2008$18.24B+36.6%
- 2007$13.35B-24.1%
- 2006$17.59B+19.4%
- 2005$14.73B-9.8%
- 2004$16.34B+39.2%
- 2003$11.74B+15.3%
- 2002$10.18B+9.9%
- 2001$9.26B+49.5%
- 2000$6.20B+102.7%
- 1999$3.06B+4.3%
- 1998$2.93B+79.8%
- 1997$1.63B-21.2%
- 1996$2.07B+13.5%
- 1995$1.82B+22.4%
- 1994$1.49B+17.9%
- 1993$1.26B+56.5%
- 1992$807.00M-4.8%
- 1991$847.60M-1.5%
- 1990$860.50M+31.2%
- 1989$655.80M—
Operating Cash Flow values are taken from Pfizer's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Pfizer (PFE)
Operating Cash Flow for Pfizer (PFE): headline value $2.62B · YoY -8.2%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Pfizer (PFE) reported operating cash flow of $11.71B – declined 8.2% year-over-year.
Pfizer operating cash flow compound annual growth for the 2020–2025 (5 years) window is -4.1%, with a net decline across the window.
Pfizer operating cash flow peaked at $32.58B in 2021; the latest annual figure is $11.71B in 2025 (64.1% below peak).
$32.58B stands as the all-time-high annual operating cash flow, posted in 2021, against a low of $655.80M during 1989.
Pfizer Operating Cash Flow by Year
Pfizer Operating Cash Flow 2025: $11.71B
In 2025, Pfizer reported operating cash flow of $11.71B, declined 8.2% below 2024.
Pfizer Operating Cash Flow 2024: $12.74B
Pfizer operating cash flow in 2024 was $12.74B, surged 46.5% from 2023.
Pfizer Operating Cash Flow 2023: $8.70B
2023's operating cash flow for Pfizer came in at $8.70B, plunged 70.3% below 2022.
Pfizer Operating Cash Flow 2022: $29.27B
Pfizer posted operating cash flow of $29.27B in 2022, declined 10.2% below 2021.
Pfizer Operating Cash Flow 2021: $32.58B
Pfizer operating cash flow in 2021 was $32.58B.
See more financial history for Pfizer (PFE).
Sector peers by Operating Cash Flow
Healthcare peers of Pfizer (PFE), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation